Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hankook Liposome Co. Ltd. is currently active in the Biotechnology & Pharmaceuticals technology area. The company's portfolio includes 1 pending office action, which is situated within 1 distinct art unit. This concentration indicates a very specific technical focus for the company's current intellectual property efforts at the USPTO, with no divergence into secondary technical fields.
The prosecution of this matter is handled by 1 distinct examiner. ROSSI, JULIA ANNE LORRAIN is the busiest examiner for the portfolio, currently overseeing the 1 pending office action. For the patent practitioner, this means that ROSSI, JULIA ANNE LORRAIN is the exclusive individual responsible for reviewing the company's pending claims. This creates a singular channel for communication and negotiation, avoiding the complexities of managing multiple examiner personalities.
The alignment of the pending workload across a single art unit and examiner reflects a streamlined and highly focused prosecution state. There are no other pending matters to balance, allowing for a dedicated strategy centered on the current application. This administrative simplicity is characteristic of portfolios with limited active filings at the office, where ROSSI, JULIA ANNE LORRAIN manages the only active case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROSSI, JULIA ANNE LORRAIN | 1 | 45.7% | +61.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19107261 | VITAMIN C-ENCAPSULATED LIPOSOME AND PREPARATION METHOD THEREFOR | ROSSI, JULIA ANNE LORRAIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19107261 | VITAMIN C-ENCAPSULATED LIPOSOME AND PREPARATION METHOD THEREFOR | ROSSI, JULIA ANNE LORRAIN | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19107261 | VITAMIN C-ENCAPSULATED LIPOSOME AND PREPARATION METHOD THEREFOR | ROSSI, JULIA ANNE LORRAIN | 1615 | §103§112 | Non-Final OA | — | Pending | Feb 27, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHankook Liposome Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Julia Anne Lorrain Rossi has the most, with 1 of Hankook Liposome Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
